Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Reduction of VLDL secretion decreases cholesterol excretion in niemann-pick C1-like 1 hepatic transgenic mice.

Marshall SM, Kelley KL, Davis MA, Wilson MD, McDaniel AL, Lee RG, Crooke RM, Graham MJ, Rudel LL, Brown JM, Temel RE.

PLoS One. 2014 Jan 3;9(1):e84418. doi: 10.1371/journal.pone.0084418. eCollection 2014.

2.

The low density lipoprotein receptor prevents secretion of dense apoB100-containing lipoproteins from the liver.

Larsson SL, Skogsberg J, Björkegren J.

J Biol Chem. 2004 Jan 9;279(2):831-6. Epub 2003 Oct 28.

3.

Differential impact of hepatic deficiency and total body inhibition of MTP on cholesterol metabolism and RCT in mice.

Dikkers A, Annema W, de Boer JF, Iqbal J, Hussain MM, Tietge UJ.

J Lipid Res. 2014 May;55(5):816-25. doi: 10.1194/jlr.M042986. Epub 2014 Feb 7.

5.

Acute sterol o-acyltransferase 2 (SOAT2) knockdown rapidly mobilizes hepatic cholesterol for fecal excretion.

Marshall SM, Gromovsky AD, Kelley KL, Davis MA, Wilson MD, Lee RG, Crooke RM, Graham MJ, Rudel LL, Brown JM, Temel RE.

PLoS One. 2014 Jun 5;9(6):e98953. doi: 10.1371/journal.pone.0098953. eCollection 2014.

6.

FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver.

Kim DH, Zhang T, Lee S, Calabuig-Navarro V, Yamauchi J, Piccirillo A, Fan Y, Uppala R, Goetzman E, Dong HH.

Endocrinology. 2014 Apr;155(4):1255-67. doi: 10.1210/en.2013-1856. Epub 2014 Jan 17.

7.

Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice.

Raabe M, Véniant MM, Sullivan MA, Zlot CH, Björkegren J, Nielsen LB, Wong JS, Hamilton RL, Young SG.

J Clin Invest. 1999 May;103(9):1287-98.

9.

Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver.

Mensenkamp AR, Jong MC, van Goor H, van Luyn MJ, Bloks V, Havinga R, Voshol PJ, Hofker MH, van Dijk KW, Havekes LM, Kuipers F.

J Biol Chem. 1999 Dec 10;274(50):35711-8.

10.
11.

Coordinate transcriptional repression of liver fatty acid-binding protein and microsomal triglyceride transfer protein blocks hepatic very low density lipoprotein secretion without hepatosteatosis.

Spann NJ, Kang S, Li AC, Chen AZ, Newberry EP, Davidson NO, Hui ST, Davis RA.

J Biol Chem. 2006 Nov 3;281(44):33066-77. Epub 2006 Aug 31.

12.

Genetic demonstration of intestinal NPC1L1 as a major determinant of hepatic cholesterol and blood atherogenic lipoprotein levels.

Xie P, Zhu H, Jia L, Ma Y, Tang W, Wang Y, Xue B, Shi H, Yu L.

Atherosclerosis. 2014 Dec;237(2):609-17. doi: 10.1016/j.atherosclerosis.2014.09.036. Epub 2014 Oct 17.

13.

Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis.

Post SM, de Roos B, Vermeulen M, Afman L, Jong MC, Dahlmans VE, Havekes LM, Stellaard F, Katan MB, Princen HM.

Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1551-6.

14.

Dietary plant stanol esters reduce VLDL cholesterol secretion and bile saturation in apolipoprotein E*3-Leiden transgenic mice.

Volger OL, van der Boom H, de Wit EC, van Duyvenvoorde W, Hornstra G, Plat J, Havekes LM, Mensink RP, Princen HM.

Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):1046-52.

15.

Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.

Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2589-600.

16.

Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1.

Jong MC, Dahlmans VE, van Gorp PJ, Breuer ML, Mol MJ, van der Zee A, Frants RR, Hofker MH, Havekes LM.

Arterioscler Thromb Vasc Biol. 1996 Aug;16(8):934-40.

17.

CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion.

Harada LM, Amigo L, Cazita PM, Salerno AG, Rigotti AA, Quintão EC, Oliveira HC.

Atherosclerosis. 2007 Apr;191(2):313-8. Epub 2006 Jun 27.

PMID:
16806230
18.

Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss.

Brown JM, Bell TA 3rd, Alger HM, Sawyer JK, Smith TL, Kelley K, Shah R, Wilson MD, Davis MA, Lee RG, Graham MJ, Crooke RM, Rudel LL.

J Biol Chem. 2008 Apr 18;283(16):10522-34. doi: 10.1074/jbc.M707659200. Epub 2008 Feb 14.

19.

Regulation of direct transintestinal cholesterol excretion in mice.

van der Velde AE, Vrins CL, van den Oever K, Seemann I, Oude Elferink RP, van Eck M, Kuipers F, Groen AK.

Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G203-G208. doi: 10.1152/ajpgi.90231.2008. Epub 2008 May 29.

20.

Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.

Han S, Liang CP, Westerterp M, Senokuchi T, Welch CL, Wang Q, Matsumoto M, Accili D, Tall AR.

J Clin Invest. 2009 Apr;119(4):1029-41. doi: 10.1172/JCI36523. Epub 2009 Mar 9.

Supplemental Content

Support Center